Skip to main content

Table 1 Baseline Patient Characteristics

From: Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Characteristics

No (%)n = 90

Mean age, years (SD)

65 (9.88)

Male Gender

67 (74)

ECOG PS

 0

34 (41)

 1

33 (40)

  > 2

15 (18)

IMDC Risk Group

 Favorable

12 (14)

 Intermediate

61 (69)

 Poor

15 (17)

 Prior Nephrectomy

67 (97)

 No of prior systemic therapies, median, No. (range)

2 (1, 6)

No of prior systemic therapies

 1

42 (47)

 2

24 (27)

 3

16 (18)

 4

6 (7)

  > 5

2 (2)

Most common prior systemic therapies

 Sunitinib

64 (71)

 Pazopanib

30 (33)

 Axitinib

35 (39)

Sites of metastases at baseline

 Brain

14 (16)

 Bones

37 (41)

 Lungs

65 (72)

 Liver

27 (30)

 Lymph Nodes

58 (64)

 Pleural

18 (20)

 Adrenal

20 (22)